Jin, J., Ginde, V., Huhn, S., Reichert, P., Bertsch, U., Fenk, R., Besemer, B., Boquoi, A., Schroers, R., Von Metzler, I., Hänel, M., Mann, C., Leypoldt, L., Heilmeier, B., Scheid, C., Peters-Regehr, T., Blau, I., Müller-Tidow, C., Luntz, S., Holderried, T., Trautmann-Grill, K., Gezer, D., Klaiber-Hakimi, M., Müller, M., Shumilov, E., Knauf, W., Michel, C., Geer, T., Riesenberg, H., Lutz, C., Raab, M., Weinhold, N., Hoffmann, M., Benner, A., Findeisen, P., Weisel, K., Salwender, H., Goldschmidt, H. and Mai, E. (2026) “P11 | PERIPHERAL MEASURABLE RESIDUAL DISEASE ACTIVITY ASSESSMENT BY MALDI-TOF MASS SPECTROMETRY IN PATIENTS WITH NEWLY-DIAGNOSED MULTIPLE MYELOMA IN THE PHASE 3 GMMG-HD7 TRIAL”, Haematologica. Pavia, Italy, 111(s2). doi: 10.3324/haematol.2026.s2.14035.